Triggering receptor expressed on myeloid cells-2 (TREM-2) elicited by lung cancer cells to facilitate tumor immune evasion.

Yao, Yinan; Li, Hequan; Wang, Yuehong; Zhou, Jianying

doi:10.1200/jco.2013.31.15_suppl.e22054

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, TREM2 expression levels in LUSC and LUAD were lower than those in normal tissues. Although the expression level of TREM2 was generally low in the entire tumor tissue, Yao et al ( 26 ) reported that TREM2 expression was up-regulated on monocytes from patients with lung cancer compared with those from healthy individuals.…”

Section: Discussionmentioning

confidence: 99%

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker

et al. 2021

View full text Add to dashboard Cite

Triggering receptor expressed on myeloid cells-2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily and a crucial signaling hub for multiple pathological pathways that mediate immunity. Although increasing evidence supports a vital role for TREM2 in tumorigenesis of some cancers, no systematic pan-cancer analysis of TREM2 is available. Thus, we aimed to explore the prognostic value, and investigate the potential immunological functions, of TREM2 across 33 cancer types. Based on datasets from The Cancer Genome Atlas, and the Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, cBioPortal, and Human Protein Atlas, we employed an array of bioinformatics methods to explore the potential oncogenic roles of TREM2, including analyzing the relationship between TREM2 and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration of different tumors. The results show that TREM2 is highly expressed in most cancers, but present at low levels in lung cancer. Further, TREM2 is positively or negatively associated with prognosis in different cancers. Additionally, TREM2 expression was associated with TMB and MSI in 12 cancer types, while in 20 types of cancer, there was a correlation between TREM2 expression and DNA methylation. Six tumors, including breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, kidney renal clear cell carcinoma, lung squamous cell carcinoma, skin cutaneous melanoma, and stomach adenocarcinoma, were screened out for further study, which demonstrated that TREM2 gene expression was negatively correlated with infiltration levels of most immune cells, but positively correlated with infiltration levels of M1 and M2 macrophages. Moreover, correlation with TREM2 expression differed according to T cell subtype. Our study reveals that TREM2 can function as a prognostic marker in various malignant tumors because of its role in tumorigenesis and tumor immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker

et al. 2021

View full text Add to dashboard Cite

show abstract

“…TREM-2 is also suggested to act as an oncogene in glioma (17). Moreover, TREM-2 is proven to promote tumor immune evasion in lung cancer cells (18). Inspired by the association between TREMs and human cancers, we sought to reveal the role of TREM-2 in RCC.…”

Section: Discussionmentioning

confidence: 99%

“…with tumor immune evasion in lung cancer (18). Whereas, the effects of TREM-2 on RCC are still less known.…”

Section: Depletion Of the Triggering Receptor Expressed On Myeloid Cementioning

confidence: 99%

Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway

Zhang

Lü

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

The triggering receptor expressed on myeloid cells 2 (TREM-2) is suggested to be involved in the development of certain human malignancies. However, the functions of TREM-2 in renal cell carcinoma (RCC) are still less known. To reveal the effects of TREM-2 on the RCC progression, we examined the TREM-2 expression in RCC tumor tissues. Then, we analyzed the cell proliferation, cell apoptosis, cell cycle and expression of the relative factors in two selected RCC cell lines post RNA interference. We also analyzed the functions of TREM-2 in an in vivo nude mouse model. We found that, the expression of TREM-2 was abnormally elevated in RCC tumor tissues. Silencing TREM-2 inhibited cell growth, induced G1 phase arrest of cell cycle and cell apoptosis in RCC cells. In vivo, the results showed that depletion of TREM-2 significantly inhibited the ACHN tumor growth in the nude mouse model. The analysis of relative protein factors suggested that silencing TREM-2 downregulated the expression levels of Bcl2 and PCNA, and upregulated the expression levels of Bax and caspase-3 in RCC cell lines. Depletion of TREM-2 inactivated PI3K/Akt pathway through increasing the expression of PTEN. Taken together, TREM-2 acts as an oncogene in the development of RCC and can be considered as a novel therapeutic factor in the treatment of RCC.

show abstract

Triggering receptor expressed on myeloid cells-2 (TREM-2) elicited by lung cancer cells to facilitate tumor immune evasion.

Cited by 2 publications

References 0 publications

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker

Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway

Contact Info

Product

Resources

About